Evidence map›Paper›PMID 20851495›Full record

ArticleImmunobiology2011

Complement mediated hepatocytes injury in a model of autoantibody induced hepatitis.

Zhidan Tu, Qing Li, Hong-Shiue Chou, Ching-Chuang Hsieh, Howard Meyerson, Marion G Peters, Hong Bu, John J Fung, Shiguang Qian, Lina Lu and 1 more

Abstract read
In one paragraph

Article in Immunobiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Zhidan TuDepartment of Pathology, Case Western Reserve University, Cleveland, OH 44106, USA.
Qing Li
Hong-Shiue Chou
Ching-Chuang Hsieh
Howard Meyerson
Marion G Peters
Hong Bu
John J Fung
Shiguang Qian
Lina Lu
Feng Lin
Case Western Reserve University · USCleveland Clinic Lerner College of Medicine · USCleveland Clinic · USSichuan University · CNUniversity of California, San Francisco · US

Funding

UCSF Liver Core CenterP30DK026743 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Holger Willenbring · 1986 to 2026
$30.7M
TISSUE CULTURE AND HYBRIDOMA MODULEP30EY011373 · NEI · CASE WESTERN RESERVE UNIVERSITY · PI CARLOS S SUBAUSTE · 1997 to 2026
$17.7M
Towards Induction of Cell Transplant ToleranceR01DK084192 · NIDDK · CLEVELAND CLINIC LERNER COM-CWRU · PI LU, LINA · 2010 to 2014
$1.7M
Synergy between T cells and Complement in EAER01NS052471 · NINDS · CASE WESTERN RESERVE UNIVERSITY · PI LIN, FENG C · 2005 to 2010
$1.3M
NEI NIH HHS EY11373NEI NIH HHS P30 EY011373NIDDK NIH HHS P30 DK026743NIDDK NIH HHS R01 DK084192NINDS NIH HHS NS052471NINDS NIH HHS R01 NS052471
6 · The paper itself

Abstract

Despite multiple reports on autoantibody-initiated complement activation in autoimmune hepatitis (AIH), how does the humoral immunity contribute to the pathogenesis of AIH remained unclear. In this report, by adoptively transferring a polyclonal rabbit anti-OVA antibody into Hep-OVA Tg mice in which OVA is selectively expressed on the surface of hepatocytes, we found that excessive complement activation initiated by the autoantibody overwhelmed the protection of intrinsic cell surface complement regulators, and induced hepatocytes injury both in vitro and in vivo. The anti-OVA antibody induced hepatic injury in Hep-OVA Tg but not WT C57BL/6 mice as assessed by serum ALT levels and liver histopathology. Immunohistochemical analyses showed that after the antibody administration, there was massive complement activation on anti-OVA IgG coated hepatocytes in Hep-OVA Tg mice, but not in WT mice. Consistent with these results, depleting complement by cobra venom factor (CVF) prior to antibody injections protected Hep-OVA Tg mice from anti-OVA IgG induced hepatic injury. In addition, treating Hep-OVA Tg mice with recombinant mouse decay accelerating factor, a native complement inhibitor, protected them from autoantibody induced hepatitis. These results suggest that complement could play a pivotal role in liver specific autoantibody mediated hepatocyte injury in AIH, and that complement inhibitors could be, in principle, developed as novel therapeutics against AIH.

Indexed as

HepatocytesAdjuvants, ImmunologicAnimalsAutoantibodiesCD55 AntigensCD59 AntigensComplement ActivationComplement System ProteinsDisease Models, AnimalHepatitis, AutoimmuneLiverMaleMiceMice, Inbred C57BLMice, TransgenicReceptors, ComplementAdjuvants, ImmunologicAutoantibodiesCD55 AntigensCD59 AntigensComplement System ProteinsCr1l protein, mouseReceptors, ComplementReceptors, Complement 3b

Identifiers

PMID20851495
PMCPMC3557916
OpenAlexW2019898385

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.